Navigation Links
Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy
Date:5/17/2013

MIAMI, May 17, 2013 /PRNewswire/ -- Insero Health, Inc., a company developing natural compounds to address unmet medical needs in epilepsy and related neurological disorders, is today reporting top-line results from a Phase Ib trial of its lead compound INS001 in patients with drug-resistant epilepsy.  The data are being presented at the AntiEplileptic Drug and Device Trials (AED) Xll meeting by Dr. Steven Schachter , Harvard Medical School epileptologist and Chairman of Insero's Scientific Advisory Board.  In this study, INS001 appeared safe and well tolerated.

INS001 is a naturally occurring compound that has shown promising activity in multiple preclinical epilepsy models.  Insero researchers believe that INS001 exerts its anti-epileptic effects through a unique combination of mechanisms: it is both a potent acetylcholinesterase inhibitor and an NMDA-receptor antagonist.  The compound has previously demonstrated good safety and signs of therapeutic activity in a Phase II trial in Alzheimer's disease, as well as in preclinical models of multiple sclerosis and neuropathic pain.

The Phase I trial was a single-center, inpatient, open-label, rapid dose escalation study in patients with drug-resistant epilepsy.  INS001 was safe and well tolerated at doses expected to be therapeutic, and increased cardiac parasympathetic tone and electrical stability were observed.

Dr. Schachter noted, "The positive safety demonstrated in this first trial of INS001 in drug-resistant epilepsy is a step forward in the clinical development of this therapy as a potential new treatment option for patients with epilepsy whose seizures are inadequately treated today."

Insero expects to initiate a Phase II proof of principle trial in patients with drug-resistant epilepsy by early next year.

Epilepsy affects about three million people in the U.S. and over 50 million people worldwide.  Many people with epilepsy take multiple medications, yet the published literature suggests that as many as one-third are unable to control their seizures with current therapies.  INS001 has a unique mechanism of action that suggests it could potentially provide superior efficacy either as a stand-alone therapy or when given in combination with other epilepsy drugs.

The Antiepileptic Drug and Device Trials (AED) XII Conference is sponsored by the Epilepsy Study Consortium in collaboration with the University of Pennsylvania Epilepsy Center and the Epilepsy Therapy Project, an initiative of the Epilepsy Foundation.  For more information, visit www.epilepsy.com/etp/aedtrialxii.

About Insero Health
Insero Health is a clinical-stage company that discovers and develops small molecule therapies derived from natural products to address significant unmet needs in neurological diseases.  The company's initial target is epilepsy, a debilitating disorder that affects approximately 3 million people in the U.S. and over 50 million people worldwide.  The company is based in Miami, Florida, at the University of Miami Life Science and Technology Park.  For more information, visit www.inserohealth.com.

Contact:
BLL Partners, LLC
Barbara Lindheim
212 584-2276
blindheim@bllbiopartners.com 

 


'/>"/>
SOURCE Insero Health, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013
2. Best Practices for Tracking Tissue in the Healthcare Supply Chain, Webinar Hosted by Xtalks
3. Cambrex To Present At UBS Global Healthcare Conference
4. Ampio Pharmaceuticals Announces Participation at the UBS Global Healthcare Conference
5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
6. ViroPharma To Participate In Two May Healthcare Investor Conferences
7. PrimeraDx Featured in the Goldman Sachs Healthcare Research Teams GS Emerging Healthcare Series
8. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
9. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
10. CellHealth Institute is Named 2013 Edison Award Winner
11. AtheroNova Announces Approval for Phase 1 by the Russian Ministry of Healthcare with Commencement of Human Trials Imminent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... ... January 11, 2017 , ... While the most ... it is becoming increasingly clear that the evolution and transmission dynamics of resistance ... in the study of clinical resistance, has vastly underestimated these reservoirs of resistance ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... cellular response analysis platform to measure the proteomic function of individual cells in ... Innovation Research (SBIR) grant from the National Institute on Aging of the National ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... announced today that the National Science Foundation (NSF) has awarded Symbios a ... will be used to commercialize the Symbios Tubular Plasma Reactor™ (TPR™) by scaling ...
(Date:1/11/2017)... Orleans, La. (PRWEB) , ... January 11, 2017 ... ... a European business development professional has joined its team. Bernhard Bartylla will lead ... , “We’re working with Bernhard to introduce ACOMP and ARGEN to European manufacturers ...
Breaking Biology Technology:
(Date:12/15/2016)... 2016 "Increase in mobile transactions is driving ... biometrics market is expected to grow from USD 4.03 ... at a CAGR of 29.3% between 2016 and 2022. ... growing demand for smart devices, government initiatives, and increasing ... component is expected to grow at a high rate ...
(Date:12/7/2016)... , December 7, 2016 BioCatch , the ... of its patent portfolio, which grew to over 40 granted and pending ... , , ... filed patent entitled " System, Device, and Method Estimating Force ... enables device makers to forego costly hardware components needed to estimate the ...
(Date:12/6/2016)... Dec. 6, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... today a five (5) year funding commitment by ... expand the rehabilitation and reentry support to more ... Established in 2004, the Prison Entrepreneurship Program (PEP) ...
Breaking Biology News(10 mins):